ReviewFuture medicinal chemistry2013
Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria.
Review in Future medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 74 citations in OpenAlex.
- Scorpion gut microbiomes as a source of bioactive and rare actinobacteria with nonribosomal peptide potential.Antonie van Leeuwenhoek · 2026Article
- Article
- Comparative Genomic Analysis of Three Paenibacillus polymyxa Strains Isolated from Termitarium and Identification of Novel Biosynthetic Gene Clusters.Current microbiology · 2025Article
- Multifunctional metal-organic frameworks as promising nanomaterials for antimicrobial strategies.Burns & trauma · 2025Review
- The endophytic fungusCurrent research in microbial sciences · 2025Article
- Discovery of a family of menaquinone-targeting cyclic lipodepsipeptides for multidrug-resistant Gram-positive pathogens.Communications biology · 2024Article
- Recent Advances in Marine-Derived Compounds as Potent Antibacterial and Antifungal Agents: A Comprehensive Review.Marine drugs · 2024Review
- Physiochemical interaction between osmotic stress and a bacterial exometabolite promotes plant disease.Nature communications · 2024Article
- Biocontrol of Soft RotMicroorganisms · 2023Article
- Design and Synthesis of Novel Antimicrobial Agents.Antibiotics (Basel, Switzerland) · 2023Review
- Bioactive Lipodepsipeptides Produced by Bacteria and Fungi.International journal of molecular sciences · 2022Review
- Bacterial Lipodepsipeptides and Some of Their Derivatives and Cyclic Dipeptides as Potential Agents for Biocontrol of Pathogenic Bacteria and Fungi of Agrarian Plants.Journal of agricultural and food chemistry · 2022Article
- Polymer Conjugates of Antimicrobial Peptides (AMPs) with d-Amino Acids (d-aa): State of the Art and Future Opportunities.Pharmaceutics · 2022Review
- Identification of structurally diverse menaquinone-binding antibiotics with in vivo activity against multidrug-resistant pathogens.Nature microbiology · 2022Article
- Characterization of Iturin V, a Novel Antimicrobial Lipopeptide from a Potential Probiotic Strain Lactobacillus sp. M31.Probiotics and antimicrobial proteins · 2021Article
- Whole-Genome Sequence Analysis of Paenibacillus alvei JR949 Revealed Biosynthetic Gene Clusters Coding for Novel Antimicrobials.Current microbiology · 2021Article
- Novel Cyclic Lipopeptides Fusaricidin Analogs for Treating Wound Infections.Frontiers in microbiology · 2021Article
- Mining the Yucatan Coastal Microbiome for the Identification of Non-Ribosomal Peptides Synthetase (NRPS) Genes.Toxins · 2020Article
- Identification of the Molecular Determinants Involved in Antimicrobial Activity of Pseudodesmin A, a Cyclic Lipopeptide From the Viscosin Group.Frontiers in microbiology · 2020Article
- Identification of Antimicrobial Compounds fromPlants (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
In order to provide effective treatment options for infections caused by multidrug-resistant bacteria, innovative antibiotics are necessary, preferably with novel modes of action and/or belonging to novel classes of drugs. Naturally occurring cyclic lipodepsipeptides, which contain one or more ester bonds along with the amide bonds, have emerged as promising candidates for the development of new antibiotics. Some of these natural products are either already marketed or in advanced stages of clinical development. However, despite the progress in the development of new antibacterial agents, it is inevitable that resistant strains of bacteria will emerge in response to the widespread use of a particular antibiotic and limit its lifetime. Therefore, development of new antibiotics remains our most efficient way to counteract bacterial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.